Human Embryonic Stem Cells Market Introduction and Overview
According to SPER market research, ‘Human Embryonic Stem Cells Market Size- By Application – Regional Outlook, Competitive Strategies and Segment Forecast to 2034’ state that the Global Human Embryonic Stem Cells Market is predicted to reach 6.1 billion by 2034 with a CAGR of 10.73%.
Human embryonic stem cells (hESCs) are Pluripotent cells produced from the inner cell mass of blastocysts, which are early-stage embryos that form five to seven days after fertilization. These cells are extremely useful in regenerative medicine and scientific study because of their exceptional capacity to self-renew indefinitely and specialize into any type of cell found in the human body, including blood, muscle, and nerve cells.
Restraints: Despite its potential, the market for human embryonic stem cells is beset with difficulties. Strict regulatory frameworks resulting from ethical concerns over the use of embryos in research impede advancement. Therapeutic uses are further complicated by technical issues like the possibility of teratoma development and immunological rejection. The market’s expansion is also impacted by public misperceptions and resistance, as well as competition from other stem cell sources including induced pluripotent stem cells (iPSCs).
Scope of the Report:
Report Metric Details
Market size available for years 2021-2034
Base year considered 2024
Forecast period 2025-2034
Segments covered By Application.
Regions covered
North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa.
Companies Covered
Thermo Fisher Scientific, Inc., STEMCELL Technologies, Merck KGaA, CellGenix GmbH, PromoCell GmbH, Takara Bio, Lonza, ATCC, Cellartis AB, Accegen, Cell Applications, Inc., Bio-Techne. and others.
Human Embryonic Stem Cells Market Segmentation:
By Application: Based on the Application, Global Human Embryonic Stem Cells Market is segmented as; Regenerative Medicine, Stem Cell Biology Research, Tissue Engineering, Toxicology Testing.
By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe and Middle East & Africa.
- 1. Introduction
- 1.1. Scope of the report
- 1.2. Market segment analysis
- 2. Research Methodology
- 2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
- 2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
- 2.3. Data triangulation
- 3. Executive Summary
- 4. Market Dynamics
- 4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges
- 5. Market variable and outlook
- 5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
- 5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
- 5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
- 5.4. Heat Map Analysis
- 6. Competitive Landscape
- 6.1. Global Human Embryonic Stem Cells Market Manufacturing Base Distribution, Sales Area, Product Type
- 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Human Embryonic Stem Cells Market
- 7. Global Human Embryonic Stem Cells Market, By Application (USD Million) 2021-2034
- 7.1. Regenerative Medicine
- 7.2. Stem Cell Biology Research
- 7.3. Tissue Engineering
- 7.4. Toxicology Testing
- 8. Global Human Embryonic Stem Cells Market, (USD Million) 2021-2034
- 8.1. Global Human Embryonic Stem Cells Market Size and Market Share
- 9. Global Human Embryonic Stem Cells Market, By Region, (USD Million) 2021-2034
- 9.1. Asia-Pacific
- 9.1.1. Australia
- 9.1.2. China
- 9.1.3. India
- 9.1.4. Japan
- 9.1.5. South Korea
- 9.1.6. Rest of Asia-Pacific
- 9.2. Europe
- 9.2.1. France
- 9.2.2. Germany
- 9.2.3. Italy
- 9.2.4. Spain
- 9.2.5. United Kingdom
- 9.2.6. Rest of Europe
- 9.3. Middle East and Africa
- 9.3.1. Kingdom of Saudi Arabia
- 9.3.2. United Arab Emirates
- 9.3.3. Qatar
- 9.3.4. South Africa
- 9.3.5. Egypt
- 9.3.6. Morocco
- 9.3.7. Nigeria
- 9.3.8. Rest of Middle-East and Africa
- 9.4. North America
- 9.4.1. Canada
- 9.4.2. Mexico
- 9.4.3. United States
- 9.5. Latin America
- 9.5.1. Argentina
- 9.5.2. Brazil
- 9.5.3. Rest of Latin America
- 10. Company Profile
- 10.1. Thermo Fisher Scientific, Inc.
- 10.1.1. Company details
- 10.1.2. Financial outlook
- 10.1.3. Product summary
- 10.1.4. Recent developments
- 10.2. STEMCELL Technologies
- 10.2.1. Company details
- 10.2.2. Financial outlook
- 10.2.3. Product summary
- 10.2.4. Recent developments
- 10.3. Merck KGaA
- 10.3.1. Company details
- 10.3.2. Financial outlook
- 10.3.3. Product summary
- 10.3.4. Recent developments
- 10.4. Sartorius AG
- 10.4.1. Company details
- 10.4.2. Financial outlook
- 10.4.3. Product summary
- 10.4.4. Recent developments
- 10.5. PromoCell GmBH
- 10.5.1. Company details
- 10.5.2. Financial outlook
- 10.5.3. Product summary
- 10.5.4. Recent developments
- 10.6. Takara Bio
- 10.6.1. Company details
- 10.6.2. Financial outlook
- 10.6.3. Product summary
- 10.6.4. Recent developments
- 10.7. Lonza
- 10.7.1. Company details
- 10.7.2. Financial outlook
- 10.7.3. Product summary
- 10.7.4. Recent developments
- 10.8. Cellartis AB
- 10.8.1. Company details
- 10.8.2. Financial outlook
- 10.8.3. Product summary
- 10.8.4. Recent developments
- 10.9. ATCC
- 10.9.1. Company details
- 10.9.2. Financial outlook
- 10.9.3. Product summary
- 10.9.4. Recent developments
- 10.10. AcceGen
- 10.10.1. Company details
- 10.10.2. Financial outlook
- 10.10.3. Product summary
- 10.10.4. Recent developments
- 10.11. Others
- 11. Conclusion
- 12. List of Abbreviations
- 13. Reference Links
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook